| Literature DB >> 25855971 |
Khachapon Nimdet1, Nathorn Chaiyakunapruk2, Kittaya Vichansavakul1, Surachat Ngorsuraches1.
Abstract
BACKGROUND: A number of studies have been conducted to estimate willingness to pay (WTP) per quality-adjusted life years (QALY) in patients or general population for various diseases. However, there has not been any systematic review summarizing the relationship between WTP per QALY and cost-effectiveness (CE) threshold based on World Health Organization (WHO) recommendation.Entities:
Mesh:
Year: 2015 PMID: 25855971 PMCID: PMC4391853 DOI: 10.1371/journal.pone.0122760
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Flow diagram of study selection.
Methodology difference in WTP per QALY.
|
|
|
|
|---|---|---|
| Total number or articles reviewed | 14 | |
|
| ||
|
| 1 (7.14) | [ |
|
| 3 (21.43) | [ |
|
| 4 (28.57) | [ |
|
| 6 (42.86) | [ |
|
| ||
|
| 7 (50.00) | [ |
|
| 3 (21.43) | [ |
|
| 3 (21.43) | [ |
|
| 1 (7.14) | [ |
|
| ||
|
| 9 (64.29) | [ |
|
| 3 (21.43) | [ |
|
| 2 (14.29) | [ |
|
| ||
|
| 3 (21.43) | [ |
|
| 4 (28.57) | [ |
|
| 7 (50.00) | [ |
|
| ||
|
| 10 (71.43) | [ |
|
| 2 (14.29) | [ |
|
| 1 (7.14) | [ |
|
| 1 (7.14) | [ |
|
| ||
|
| 5 (35.71) | [ |
|
| 3 (21.43) | [ |
|
| 2 (14.29) | [ |
|
| 4 (28.57) | [ |
|
| ||
|
| ||
|
| 1 (7.14) | [ |
|
| 3 (21.43) | [ |
|
| 2 (7.14) | [ |
|
| 1 (7.14) | [ |
|
| 2 (14.29) | [ |
|
| 1 (7.14) | [ |
|
| 1 (7.14) | [ |
|
| 1 (7.14) | [ |
|
| 1 (7.14) | [ |
|
| ||
|
| 1 (7.14) | [ |
|
| ||
|
| 13 (92.86) | [ |
|
| 1 (7.14) | [ |
|
| ||
|
| 1 (7.14) | [ |
|
| ||
|
| 1 (7.14) | [ |
|
| 1 (7.14) | [ |
|
| 1 (7.14) | [ |
|
| 1 (7.14) | [ |
|
| 1 (7.14) | [ |
|
| 2 (14.29) | [ |
|
| ||
|
| 3 (21.43) | [ |
|
| 1 (7.13) | [ |
|
| ||
|
| 1 (7.14) | [ |
|
| 1 (7.14) | [ |
|
| ||
|
| 1 (7.14) | [ |
|
| 5 (35.71) | [ |
|
| 6 (42.89) | [ |
|
| 2 (14.29) | [ |
WTP per QALY compared to GDP per Capita.
|
|
|
|
|
|
|
|
| No of Respondents | WTP/QALY ($) | WTP/QALY compared to GDP per capita (times) |
|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||
|
| 1995 | HRT | Improving QoL | 1 | 2 | Sweden | Patient | 104 | 120,000–160,000 | 0.63–0.84 |
|
| 2001 | Knee osteoarthritis | Improving QoL | 3 | 9 | US | GP | 193 | 2,019–35,257 | 0.05–0.95 |
| Current HS | ||||||||||
|
| 2005 | Herpes zoster | Improving QoL | 9 | 9 | US | Patient | 474 | 26,000–45,000 | 0.52–1.02 |
| GP | 478 | |||||||||
|
| 2007 | EQ-5D HS | Improving QoL | 13 | 13 | Spain | GP | 560 | 11,999–182,134 | 0.26–3.91 |
|
| 2008 | Allergy, Paralysis, and Blindness | Improving QoL | 12 | 12 | Thailand | GP | 1,191 | 1,698–17,283 | 0.20–2.06 |
|
| 2008 | EQ-5D HS | Improving QoL | 29 | 4 | Netherland | GP | 1,091 | 13,360–34,097 | 0.25–0.64 |
|
| 2009 | Serious illness | Extending life | 4 | 3 | Japan | GP | 1,114 | 44,000–47,000 | 1.16–1.23 |
| Serious illness | Extending life | 4 | 3 | ROK | GP | 1,000 | 79,000–90,000 | 3.42–3.90 | ||
| Serious illness | Extending life | 4 | 3 | Taiwan | GP | 504 | 70,000–84,000 | 4.03–4.82 | ||
| Serious illness | Extending life | 4 | 3 | UK | GP | 1,002 | 39,000–61,000 | 0.81–1.28 | ||
| Serious illness | Extending life | 4 | 3 | Australia | GP | 1,000 | 50,000–68,000 | 1.22–1.66 | ||
| Serious illness | Extending life | 4 | 3 | US | GP | 1,000 | 56,000–66,000 | 1.16–1.36 | ||
|
| 2009 | EQ-5D HS | Improving QoL | 12 | 12 | Japan | GP | 2,400 | 24,375–121,876 | 0.53–2.64 |
| Dead state | Extending life | 2 | 2 | Japan | GP | 2,400 | 70,567–71,913 | 1.52–1.56 | ||
| Dead state | Saving life | 2 | 2 | Japan | GP | 2,400 | 37,797–72,317 | 0.82–1.56 | ||
|
| 2009 | Current HS | Improving QoL | 1 | 2 | China | GP | 364 | 4,711–5,012 | 0.72–0.77 |
| Current HS | Imoroving QoL | 1 | 2 | China | Patient | 286 | 7,408–7,306 | 1.12–1.13 | ||
|
| 2010 | Viral illness | Improving QoL | 29 | 2 | Netherland | GP | 1,004 | 159,810–252,408 | 3.42–5.40 |
|
| Current HS | Improving QoL | 1 | 3 | US | Patient | 391 | 12,500–32,200 | 0.32–0.81 | |
|
| 2010 | EQ-5D HS | Improving QoL | 27 | 8 | Netherland | GP | 2,510 | 3,412–7,904 | 0.07–0.17 |
| EQ-5D HS | Improving QoL | 27 | 8 | UK | GP | 2,312 | 6,775–3,256 | 0.09–0.18 | ||
| EQ-5D HS | Improving QoL | 27 | 8 | France | GP | 2,674 | 3,256–6,775 | 0.08–0.18 | ||
| EQ-5D HS | Improving QoL | 27 | 8 | Spain | GP | 2,697 | 6,671–12,669 | 0.22–0.43 | ||
| EQ-5D HS | Improving QoL | 27 | 8 | Sweden | GP | 2,604 | 3,235–7,842 | 0.07–0.16 | ||
| EQ-5D HS | Improving QoL | 27 | 8 | Norway | GP | 2,020 | 7,659–15,472 | 0.09–0.18 | ||
| EQ-5D HS | Improving QoL | 27 | 8 | Denmark | GP | 2,637 | 5,749–15,409 | 0.10–0.27 | ||
| EQ-5D HS | Improving QoL | 27 | 8 | Poland | GP | 2,173 | 3,611–10,744 | 0.29–0.87 | ||
| EQ-5D HS | Improving QoL | 27 | 8 | Hungary | GP | 2,287 | 3,611–10,748 | 0.24–0.60 | ||
|
| 2011 | Current HS | Improving QoL | 1 | 2 | US | Patient | 757 | 10,119–10,305 | 0.42–0.43 |
|
| ||||||||||
|
| 2001 | Chronic HS | Improving QoL | 23 | 1 | Denmark | GP | 3,201 | 10,972 | 0.37 |
Abbreviations: GDP, gross domestic product; No, number; HRT, hormone replacement therapy; HS, health state, No, number; GP, general population; QoL, quality of life;UK, united Kingdom;
ROK, Republic of Korea; US, United states;
¶ mild or severe osteoarthritis;
*EQ-5D described severity;
^ CSM,general medical clinic,cerebral aneurysms;
^^Knee osteoarthritis;
€chronic prostatitis
Exploration of the relationship between numerous factors associated with the ratio of WTP per QALY compared to GDP per capita.
| Factors | Mean of WTP per QALY compared to GDP per capita | Mean difference (times) (95% CI) | P value |
|---|---|---|---|
|
| |||
|
| |||
|
| 0.59 |
| |
|
| 2.03 | -1.43 (-1.81 to -1.06) | < 0.01 |
|
| |||
|
| 0.63 |
| |
|
| 2.16 | -1.53 (-2.00 to -1.06) | < 0.01 |
|
| |||
|
| 0.37 |
| |
|
| 0.70 | -0.32 (-0.61 to -0.03) | 0.03 |
|
| 1.65 | -1.28 (-1.62 to -0.93) | < 0.01 |
|
| |||
|
| 0.45 |
| |
|
| 1.45 | -1.00 (-1.28 to -0.72) | < 0.01 |
|
| |||
|
| 1.30 |
| |
|
| 0.71 | 0.59 (0.15 to 1.02) | 0.01 |
|
| |||
|
| |||
|
| 0.82 |
| |
|
| 0.70 | 0.12 (-0.53 to 0.77) | 0.72 |
|
| 0.51 | 0.31 (-0.17 to 0.78) | 0.96 |
|
| |||
|
| |||
|
| 0.97 |
| |
|
| 0.75 | 0.35 (-0.24 to 0.68) | 0.35 |
|
| |||
|
| 0.80 |
| |
|
| 1.62 | -0.82 (-1.31 to -0.33) | 0.01 |
|
| |||
|
| -0.30 (-0.43 to -0.17) | < 0.01 |
Abbreviations: GDP, gross domestic product; SD, standard deviation; CI, confidence interval; n, number of study
* no statistical significance
§ Comparator